Top Continuous Glucose Monitoring Devices Companies

Continuous Glucose Monitoring Devices Market size was valued at USD 8.4 Billion in 2023 and is poised to grow from USD 8.82 Billion in 2024 to USD 13.03 Billion by 2032, growing at a CAGR of 5% during the forecast period (2025-2032).

The competitive landscape of the global continuous glucose monitoring devices market is characterized by intense rivalry among key players aiming to capture a significant share. Industry leaders like Abbott, Dexcom, and Medtronic maintain dominant positions owing to their extensive product portfolios, technological innovation, and established market presence. These companies continuously invest in research and development to enhance device accuracy, user-friendliness, and connectivity. 'Abbott (USA)', 'Dexcom (USA)', 'Medtronic (Ireland)', 'Roche Diagnostics (Switzerland)', 'Senseonics Holdings (USA)', 'Lifespan (South Korea)', 'Ascensia Diabetes Care (Switzerland)', 'Nemaura Medical (UK)', 'Ypsomed (Switzerland)', 'Glysens (USA)', 'Tandem Diabetes Care (USA)', 'MedAngel (Belgium)', 'Bigfoot Biomedical (USA)', 'Novo Nordisk (Denmark)', 'Sensionics (USA)', 'MicroPort (China)', 'Insulet Corporation (USA)', 'GluSense (Israel)', 'DarioHealth (USA)', 'Admetsys (USA)'

The increasing global prevalence of diabetes is a significant driver, necessitating effective monitoring and management solutions like continuous glucose monitoring devices.

Integration with Digital Health Platforms: Continuous glucose monitoring devices are increasingly being integrated with digital health platforms, allowing users to track and manage their data seamlessly alongside other health metrics.

Expected to capture the leading market share of 38.9% in 2022, the North American region is poised to maintain its preeminence throughout the projected period. This region's growth trajectory is propelled by the mounting prevalence of diabetes and proactive endeavors undertaken by national governments to address the challenge on a broader scale.